HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
Journal
Journal of Infectious Diseases
Journal Volume
202
Journal Issue
1
Pages
86-92
Date Issued
2010
Author(s)
Yu M.-L.
Lee C.-M.
Chuang W.-L.
Lu S.-N.
Dai C.-Y.
Huang J.-F.
Lin Z.-Y.
Hu T.-I.
Chen C.-H.
Hung C.-.
Wang J.-H.
Lai M.-Y.
Wu S.-S.
Liao L.-Y.
Kuo H.-T.
Chao Y.-C.
Tung S.-Y.
Yang S.-S.
Abstract
Background. With use of peginterferon alfa-2a and ribavirin combination therapy in patients with dual chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 11.2% of patients achieved clearance of hepatitis B surface antigen (HBsAg) at 6 months after treatment; however, reactivation of HBV DNA was observed in 36.3%. We investigated the predictive potential of HBsAg quantification. Methods. HBsAg quantification was performed in 120 e antigen-negative patients dually infected with HBV and hepatitis C virus and treated with peginterferon alfa-2a/ribavirin for 48 weeks (HCV genotype 1; n = 74) or 24 weeks (HCV genotype 2/3; n = 46). HBsAg was quantified at baseline, week 4, week 12, end of treatment, and 24 weeks after treatment. Results. The baseline median serum HBsAg level was 120 IU/mL and decreased gradually during treatment. Low baseline HBsAg was significantly associated with HBsAg clearance (40% for HBsAg level ?20 IU/mL vs 2.2% for HBsAg level >20 IU/mL; P< .05). A decrease in HBsAg level from baseline to week 12 of 50% was associated with a reduced likelihood of HBV DNA reactivation in patients with baseline undetectable serum HBV DNA (positive predictive value, 89.5%). Conclusions. HBsAg quantification appears to be a useful indicator of posttreatment outcome in patients dually infected with HBV and hepatitis C virus. ? 2010 by the Infectious Diseases Society of America. All rights reserved.
SDGs
Other Subjects
hepatitis B surface antigen; peginterferon alpha2a; ribavirin; virus DNA; alpha2a interferon; antivirus agent; hepatitis B surface antigen; macrogol derivative; peginterferon alfa-2a; peginterferon alpha2a; ribavirin; virus DNA; article; chronic disease; combination chemotherapy; female; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; major clinical study; male; priority journal; serodiagnosis; virus reactivation; adult; blood; drug administration; genetics; genotype; Hepatitis B virus; Hepatitis C virus; middle aged; virology; virus activation; Adult; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Interferon Alfa-2a; Male; Middle Aged; Polyethylene Glycols; Ribavirin; Virus Activation
Publisher
University of Chicago Press
Type
journal article